NE-ADJUVANCE-TECH
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research.
“The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.”
Dr. Krause previously had a 30-year career in the FDA where he made major contributions in design of clinical trials, molecular virology and immunology, and the regulation and development of vaccines. He will provide strategic consulting on vaccine development, US and international regulatory affairs, clinical trial design and evaluation, virology and immunology and global health.
Dr. Krause said, “I look forward to this opportunity to provide advice and counsel to the Adjuvance leadership team on the development of their innovative saponin adjuvant platform, and their lead vaccine candidates.”
About TQL-1055 : TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant, which is used in the currently available shingles vaccine. Saponin adjuvants are potent immune stimulators and important components of licensed, currently marketed, and clinically advanced infectious disease vaccines. The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. TQL-1055 is designed to have improved tolerability and to provide the same strong immune response as QS21 and has shown favorable tolerability in a Phase 1 clinical trial. Adjuvance is designing new combination adjuvants, with TQL-1055 as the foundation, to produce different types of immune responses.
About Shingles : Shingles (also known as herpes zoster) is a painful rash that develops, often on the face or torso, and has the potential complication of pain that can last for months or even years. Vaccination against shingles is recommended in the United States and many countries for older adults and people with weak immune systems, resulting in a market value of over $2.0 billion in 2020. Available shingles vaccines contain the saponin adjuvant QS-21 and the toll-like receptor (TLR) 4 agonist adjuvant monophosphoryl lipid A (MPL), known together as the AS01 adjuvant. The adjuvanted shingles vaccine is highly effective, but can cause short-term adverse events more intense than other vaccines. About 1 out of 6 people who got the available shingles vaccine experienced side effects that prevented them from doing regular activities. Symptoms went away on their own in about 2 to 3 days.
About Adjuvance Technologies : Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our lead vaccine candidate against shingles aims to provide a better patient experience including improved tolerability for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institutes of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005493/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThreatDown Launches Nexus Partner Program, Strengthening its Channel-First Commitment11.11.2025 15:02:00 CET | Press release
New program marks a strategic investment, putting partners at the center of ThreatDown’s growth strategy ThreatDown, the corporate business unit of Malwarebytes, today announced the launch of the Nexus Partner Program, a comprehensive initiative that puts partners at the center by strengthening collaboration and creating new growth opportunities for its global network of partners. The program aligns incentives, simplifies enablement, and strengthens collaboration to ensure every reseller has the resources and support needed to deliver smarter, stronger security outcomes for customers. “At ThreatDown, being channel-first means putting our partners at the center of everything we do,” says Kendra Krause, General Manager of ThreatDown. “The Nexus Partner Program reflects that belief – the program is built to equip partners with the tools they need to succeed in a rapidly evolving cybersecurity market. When our partners win, we win.” Available globally, the program offers competitive discou
Blue Matter Enhances Twine™ Platform Capabilities in Response to Growing Demand11.11.2025 15:01:00 CET | Press release
Blue Matter today announced the expansion of its Twine™ data platform’s capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas. Twine™ is Blue Matter's purpose-built customer intelligence platform for healthcare and life sciences companies. It transforms complex data from disparate sources including specialty pharmacy networks, hub services, claims databases, and other third party data sources into actionable insights that drive commercial strategy and operational excellence. With generative AI at its core, Twine helps companies more effectively acquire, master, validate, and analyze data from internal and third-party sources. Persona-specific outputs enable faster, more informed decision-making. According to Deepak Gopinath, Partner
Financial Sector Signals Rising Investment in Identity Verification11.11.2025 15:00:00 CET | Press release
Banks, fintechs, and crypto platforms are ramping up investment in fraud prevention and identity verification (IDV), positioning it as the next layer of cyber defense. According to Regula’s global survey, The Future of Identity Verification: 5 Threats and 5 Opportunities, banks are leading this trend: the share of institutions intending to increase IDV budgets by more than 50% is nearly tripling—from 4.4% to 15% in just two years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111008888/en/ Banks lead the IDV investment surge, but fintech, crypto, and aviation sectors are catching up fast, with roughly one in six companies planning to expand IDV budgets by more than 50%. Even healthcare is joining the trend, signaling how essential verification has become beyond finance. Moderate increases in identity verification budgets are becoming common across all financial services. Roughly a third of banks and crypto firms and a fi
Ben Mauro Announces Early Deluxe Hardcover Release of HUXLEY: The Oracle, Featuring Exclusive Art From Top Sci-Fi Artists11.11.2025 15:00:00 CET | Press release
Acclaimed concept artist and worldbuilder Ben Mauro (Halo Infinite, Call of Duty, Elysium, The Predator) is excited to announce the early shipping of the deluxe hardcover edition of HUXLEY: The Oracle, the first major prequel book in the expanding HUXLEY universe. These premium deluxe editions are shipping now in limited quantities, ahead of the worldwide release of the standard edition on December 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111345993/en/ Screenshot from HUXLEY: THE ORACLE The Oracle explores the origins of FURY-7, a scorched desert world ruled by the ancient machine empire known as the Oracles. The story follows Max, an elite Ronin enforcer, as he uncovers a conspiracy that sets the foundation for the events of the original HUXLEY graphic novels. This deluxe edition features over 100 color illustrations from leading industry artists, including Steve Chinhsuan Wang (Gears of War 5), Nikolas Gekko (H
Rigaku Holdings Issues Integrated Report 202511.11.2025 15:00:00 CET | Press release
Rigaku Holdings Corporation (Headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) issued its inaugural Integrated Report 2025 (hereinafter “the Report”) on the Rigaku website. The report serves as a medium for integrated communication with all stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111995654/en/ Integrated Report cover The Report provides an overview of Rigaku’s investments, technological innovations, business activities, and global growth strategy. It also presents Rigaku’s financial and non-financial performance for the fiscal year ending December 31, 2024. Rigaku invites readers to explore the Report to learn about its contributions to global technological advancement through X-ray diffraction solutions. Rigaku continues to strive to become a “One-of-a-Kind Global Technology Company.” The full Report can be found at: https://rigaku-holdings.com/english/ir/reports/ Comment by CEO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom